论文部分内容阅读
目的探讨卢沙坦对糖尿病足患者血管内皮功能的影响。方法将60例伴有血管内皮功能异常的2型糖尿病足病患者随机分为两组,A组接受卢沙坦口服治疗,B组口服利尿剂或α受体阻滞剂或β受体阻滞剂或无降压药,16周后检测并比较两组患者治疗前后血管内皮功能。结果 A组患者经卢沙坦治疗16周后平均内皮依赖性血管舒张功能(EDD)由(5.45±1.19)%上升至(7.11±1.62)%,内皮非依赖性血管舒张功能(EID)由(14.12±1.58)%上升至(16.03±1.51)%,两者治疗前后比较差异均有统计学意义(P<0.05);B组经治疗后的EDD、EID亦有上升,但与治疗前比较差异无统计学意义(P>0.05)。结论卢沙坦能有效地改善糖尿病足患者的血管内皮功能,并且具有良好的安全性及耐受性。
Objective To investigate the effect of rosasartan on vascular endothelial function in patients with diabetic foot. Methods Sixty diabetic foot patients with type 2 diabetes mellitus with vascular endothelial dysfunction were randomly divided into two groups: group A received oral treatment with losartan, group B received oral diuretic or α-blocker or β-blocker Or no antihypertensive drugs, 16 weeks after the detection and comparison of two groups of patients before and after treatment of vascular endothelial function. Results The mean endothelium-dependent vasodilatory function (EDD) increased from (5.45 ± 1.19)% to (7.11 ± 1.62)% in group A after 16 weeks of treatment with rosuvastatin. The endothelium-independent vasodilation function (EID) (P <0.05). The EDD and EID of group B after treatment were also increased, but compared with those before treatment, the difference was statistically significant No statistical significance (P> 0.05). Conclusion Lusartan can effectively improve the vascular endothelial function in patients with diabetic foot, and has good safety and tolerability.